Roche Reports Positive Results for Hemophilia Drug in Kids

Roche says that its emicizumab drug for treating hemophilia A showed positive interim results in a phase III study with children under 12 years old.

"At this interim analysis after a median of 12 weeks of treatment, emicizumab prophylaxis showed a clinically meaningful reduction in the number of bleeds over time," Roche said in a statement.

Roche is hoping that ACE910 will compete with more traditional treatments from Novo Nordisk and Shire.

Read the Roche press release